

Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 27, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Date: Thursday, June 3, 2021
Time: 2:30 PM ET
Format: Corporate presentation
Webcast: <https://wsw.com/webcast/jeff174/virx/1890351>

A replay of the presentation will be available on the "Events and Webcasts" section of the Viracta website at <https://viracta.investorroom.com/events-and-webcasts#past>.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:

Dan Chevallard
Chief Operating Officer and Chief Financial Officer
dchevallard@viracta.com
(858) 771-4193

SOURCE Viracta Therapeutics, Inc.

<https://viracta.investorroom.com/2021-05-27-Viracta-Therapeutics-to-Present-at-the-Jefferies-Virtual-Healthcare-Conference>